Industry Outlook

The leadless cardiac pacemakers market is set to reach from US$ 47.1 Mn in 2017 to US$ 269.8 Mn by 2026 representing outstanding growth at a compounded annual growth rate (CAGR) of 21.9% during the forecast period from 2018 to 2026. Atrial fibrillation is the most common type of cardiac arrhythmia diagnosed globally. As per the latest research citings of Global Burden of Disease (GBD) report the global prevalence rate of atrial fibrillation is 191.3 per 100,000 people. Leadless cardiac pacemakers are going to eventually replace the traditional pacemakers on account of its inherent features such as small size, less surgical complications, extended battery life, no device dislodgement and easy retrieval. Nanostim and wireless cardiac simulation systems will capture the market in the near future after FDA approval.

"Easy implantation, low device dislodgement and easy retrieval drive the micra transcatheter pacing system market growth"

Micra transcatheter pacing system (Medtronic, Plc.) are currently leading the type segment for leadless cardiac pacemakers market. It received succceful FDA approval in April 2016 owing to its inherent features such as easy implantation, low device dislodgement and easy retrieval. It is imbedded in the right ventricle via the femoral venous access which utilizes steerable delivery sheath. The nanostim leadless cardiac pacemaker system (St. Jude Medical, Inc.) was the first system to be implanted in humans for safety and efficacy studies during the LEADLESS clinical trial study. Recently it had 2 major recalls associated with premature battery failure and spontaneous detachment of the docking button. Both these system are limited to single chamber pacing specifically related to the ventricular pacing. In the near future dual chamber and multichamber pacing leadless systems will be critically studied in the clinical trial studies. Wireless cardiac simulation system (EBR Systems, Inc.) is still under investigation, it employs pulse generator which communicates with leadless pacing electrode via acoustic energy.

"Rising prevalence of cardiac arrhythmias and domicile of major players drive the market growth in North America"

Currently North America represents a share of 70% and is the global leader in leadless cardiac pacemakers market. As per the statistics provided by Center for Disease Control and Prevention (CDC), approximately 630,000 United States citizens die annually from heart disease which corresponds to 1 in every 4th individual. The primary features contributing towards its overwhelming growth are rising prevalence of cardiac arrhythmias and domicile of major players such as Medtronic, Plc., St. Jude Medical, Inc. and EBR Systems, Inc. etc. Europe holds a market share of 18% and is the second largest market in leadless cardiac pacemakers market. Rising public health awareness and affordable reimbursement scenario drive the market growth for leadless cardiac pacemakers in European region. Asia Pacific accounts for 7% market share majorly due to huge population base suffering with cardiac complications and developing healthcare infrastructure.

Medical device manufacturers actively participating in the leadless cardiac pacemakers market are Boston Scientific Corporation, EBR Systems, Inc., Medtronic, Plc., Nanostim, Inc. and St. Jude Medical, Inc.

Historical & Forecast Period

This study report represents analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Leadless Cardiac Pacemakers market are as follows:

• Research and development budgets of manufacturers and government spending
• Revenues of key companies in the market segment
• Number of end users and consumption volume, price and value.
• Geographical revenues generate by countries considered in the report
• Micro and macro environment factors that are currently influencing the Leadless Cardiac Pacemakers market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Key questions answered in this report

• What are the key micro and macro environmental factors that are impacting the growth of Leadless Cardiac Pacemakers market?
• What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
• Estimated forecast and market projections up to 2032.
• Which segment accounts for the fastest CAGR during the forecast period?
• Which market segment holds a larger market share and why?
• Are low and middle-income economies investing in the Leadless Cardiac Pacemakers market?
• Which is the largest regional market for Leadless Cardiac Pacemakers market?
• What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
• Which are the key trends driving Leadless Cardiac Pacemakers market growth?
• Who are the key competitors and what are their key strategies to enhance their market presence in the Leadless Cardiac Pacemakers market worldwide?